Skip to main content

Snapdragon finds alternative buyer in Cambrex

CDMO Cambrex has agreed to buy Snapdragon Chemistry, a US-based provider of chemical process development services to the biopharma sector. Terms were not disclosed. This came two months after regulatory approval was denied to Asymchem Laboratories’ acquisition of Snapdragon.

Cambrex expands at two US sites

Cambrex has announced it is investing in a new facility in Minneapolis. It will operate as an extension of the flagship facility in Charles City, Iowa (pictured), which is simultaneously seeing further expansion.

The new site, near Minneapolis–St. Paul Airport, will specialise in analytical and chemical development for small molecule drug candidates and will cover 1,950 m2 R&D. This will double Cambrex’s analytical and chemical development footprint in the Midwest, according to CEO Thomas Loewald, while creating 46 jobs.

Cambrex completes Estonia kilo lab

Cambrex has completed the upgrade of the kilo lab at its facility in Tallinn, Estonia, manufacture pharmaceutical intermediates to cGMP standards. The company said that this would “accelerate the progression and tech transfer of projects within the early clinical development phases”.

Cambrex expands US API capacity

Small molecule CDMO Cambrex is spending $50 million to expand its mid- and large-scale API manufacturing capacity in Charles City, Iowa. This is the sixth major investment at the site in the past eight years and follows on from a recent, smaller expansion at the site in Karlskroga, Sweden.

Cambrex invests in Sweden

Small molecule CDMO Cambrex is to spend $3.6 million to increase flexible drug substance manufacturing capacity by 6 m3 (25%) at Karlskoga, Sweden, in response to growing demand for commercial-scale API manufacturing. Engineering work has already commenced and should be completed by November.

Change at the top for CDMOs

Two of the major global pharmaceutical CDMOs, Lonza and Alcami, have announced the appointments of new CEOs in early June. There have also been changes in senior positions at Corden Pharma and, imminently, at Cambrex.

Permira buys Cambrex

Cambrex has signed a definitive agreement to be acquired by an affiliate of private equity firm Permira, which has $48 billion of committed capital in its portfolio, covering healthcare among four other sectors.
Subscribe to Cambrex